Dimensional Fund Advisors LP Has $517,000 Stock Position in Fresenius Medical Care AG (NYSE:FMS)

Dimensional Fund Advisors LP lifted its stake in Fresenius Medical Care AG (NYSE:FMS - Free Report) by 86.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 22,820 shares of the company's stock after acquiring an additional 10,600 shares during the period. Dimensional Fund Advisors LP's holdings in Fresenius Medical Care were worth $517,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. ABC Arbitrage SA acquired a new stake in Fresenius Medical Care in the 4th quarter worth $4,215,000. OLD Mission Capital LLC bought a new stake in shares of Fresenius Medical Care in the fourth quarter valued at about $3,545,000. Broyhill Asset Management acquired a new stake in Fresenius Medical Care during the fourth quarter worth about $3,412,000. Marshall Wace LLP increased its stake in Fresenius Medical Care by 128.0% during the fourth quarter. Marshall Wace LLP now owns 129,581 shares of the company's stock valued at $2,934,000 after acquiring an additional 72,740 shares during the period. Finally, Sanctuary Advisors LLC acquired a new position in shares of Fresenius Medical Care in the fourth quarter valued at $983,000. Institutional investors own 8.37% of the company's stock.

Fresenius Medical Care Trading Up 2.5%

Shares of Fresenius Medical Care stock traded up $0.73 during trading on Tuesday, hitting $29.88. 845,047 shares of the company were exchanged, compared to its average volume of 328,374. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.37 and a quick ratio of 1.02. The firm has a market capitalization of $17.53 billion, a P/E ratio of 24.69, a price-to-earnings-growth ratio of 0.76 and a beta of 0.85. The firm's fifty day moving average price is $25.08 and its 200 day moving average price is $23.80. Fresenius Medical Care AG has a 1-year low of $17.93 and a 1-year high of $30.16.

Fresenius Medical Care (NYSE:FMS - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported $0.44 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.43 by $0.01. The firm had revenue of $5.54 billion during the quarter, compared to analysts' expectations of $4.71 billion. Fresenius Medical Care had a net margin of 3.43% and a return on equity of 6.04%. As a group, sell-side analysts expect that Fresenius Medical Care AG will post 1.51 earnings per share for the current fiscal year.

Fresenius Medical Care Increases Dividend

The firm also recently disclosed an annual dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 23rd will be paid a dividend of $0.7871 per share. This represents a yield of 1.9%. The ex-dividend date of this dividend is Friday, May 23rd. This is an increase from Fresenius Medical Care's previous annual dividend of $0.44. Fresenius Medical Care's dividend payout ratio (DPR) is presently 49.11%.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on FMS shares. StockNews.com started coverage on shares of Fresenius Medical Care in a research report on Tuesday. They set a "strong-buy" rating on the stock. Truist Financial lifted their price target on Fresenius Medical Care from $25.00 to $30.00 and gave the company a "hold" rating in a report on Monday, May 12th. Finally, Morgan Stanley reiterated an "underweight" rating on shares of Fresenius Medical Care in a research report on Thursday, May 15th. One research analyst has rated the stock with a sell rating, two have given a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $27.80.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.